386 related articles for article (PubMed ID: 21644996)
1. Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain.
Boutajangout A; Ingadottir J; Davies P; Sigurdsson EM
J Neurochem; 2011 Aug; 118(4):658-67. PubMed ID: 21644996
[TBL] [Abstract][Full Text] [Related]
2. Vectored Intracerebral Immunization with the Anti-Tau Monoclonal Antibody PHF1 Markedly Reduces Tau Pathology in Mutant Tau Transgenic Mice.
Liu W; Zhao L; Blackman B; Parmar M; Wong MY; Woo T; Yu F; Chiuchiolo MJ; Sondhi D; Kaminsky SM; Crystal RG; Paul SM
J Neurosci; 2016 Dec; 36(49):12425-12435. PubMed ID: 27927959
[TBL] [Abstract][Full Text] [Related]
3. Tau-targeting passive immunization modulates aspects of pathology in tau transgenic mice.
Ittner A; Bertz J; Suh LS; Stevens CH; Götz J; Ittner LM
J Neurochem; 2015 Jan; 132(1):135-45. PubMed ID: 25041093
[TBL] [Abstract][Full Text] [Related]
4. Passive Immunization in JNPL3 Transgenic Mice Using an Array of Phospho-Tau Specific Antibodies.
d'Abramo C; Acker CM; Jimenez H; Davies P
PLoS One; 2015; 10(8):e0135774. PubMed ID: 26270821
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements.
Asuni AA; Boutajangout A; Quartermain D; Sigurdsson EM
J Neurosci; 2007 Aug; 27(34):9115-29. PubMed ID: 17715348
[TBL] [Abstract][Full Text] [Related]
6. Passive Immunization With a Novel Monoclonal Anti-PrP Antibody TW1 in an Alzheimer's Mouse Model With Tau Pathology.
Boutajangout A; Zhang W; Kim J; Abdali WA; Prelli F; Wisniewski T
Front Aging Neurosci; 2021; 13():640677. PubMed ID: 33716717
[TBL] [Abstract][Full Text] [Related]
7. Anti-tau conformational scFv MC1 antibody efficiently reduces pathological tau species in adult JNPL3 mice.
Vitale F; Giliberto L; Ruiz S; Steslow K; Marambaud P; d'Abramo C
Acta Neuropathol Commun; 2018 Aug; 6(1):82. PubMed ID: 30134961
[TBL] [Abstract][Full Text] [Related]
8. Tau passive immunization inhibits not only tau but also Aβ pathology.
Dai CL; Tung YC; Liu F; Gong CX; Iqbal K
Alzheimers Res Ther; 2017 Jan; 9(1):1. PubMed ID: 28073379
[TBL] [Abstract][Full Text] [Related]
9. Ubiquitin-negative mini-pick-like bodies in the dentate gyrus in p301l tauopathy.
Ferrer I; Hernández I; Puig B; Rey MJ; Ezquerra M; Tolosa E; Boada M
J Alzheimers Dis; 2003 Dec; 5(6):445-54. PubMed ID: 14757934
[TBL] [Abstract][Full Text] [Related]
10. Phosphorylated protein kinases associated with neuronal and glial tau deposits in argyrophilic grain disease.
Ferrer I; Barrachina M; Tolnay M; Rey MJ; Vidal N; Carmona M; Blanco R; Puig B
Brain Pathol; 2003 Jan; 13(1):62-78. PubMed ID: 12580546
[TBL] [Abstract][Full Text] [Related]
11. Tau passive immunotherapy in mutant P301L mice: antibody affinity versus specificity.
d'Abramo C; Acker CM; Jimenez HT; Davies P
PLoS One; 2013; 8(4):e62402. PubMed ID: 23638068
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model.
Boutajangout A; Quartermain D; Sigurdsson EM
J Neurosci; 2010 Dec; 30(49):16559-66. PubMed ID: 21147995
[TBL] [Abstract][Full Text] [Related]
13. Passive immunization targeting the N-terminal projection domain of tau decreases tau pathology and improves cognition in a transgenic mouse model of Alzheimer disease and tauopathies.
Dai CL; Chen X; Kazim SF; Liu F; Gong CX; Grundke-Iqbal I; Iqbal K
J Neural Transm (Vienna); 2015 Apr; 122(4):607-17. PubMed ID: 25233799
[TBL] [Abstract][Full Text] [Related]
14. Anti-tau phospho-specific Ser262 antibody recognizes a variety of abnormal hyper-phosphorylated tau deposits in tauopathies including Pick bodies and argyrophilic grains.
Ferrer I; Barrachina M; Puig B
Acta Neuropathol; 2002 Dec; 104(6):658-64. PubMed ID: 12410387
[TBL] [Abstract][Full Text] [Related]
15. Tau passive immunization blocks seeding and spread of Alzheimer hyperphosphorylated Tau-induced pathology in 3 × Tg-AD mice.
Dai CL; Hu W; Tung YC; Liu F; Gong CX; Iqbal K
Alzheimers Res Ther; 2018 Jan; 10(1):13. PubMed ID: 29386065
[TBL] [Abstract][Full Text] [Related]
16. Phosphorylated p38MAPK specific antibodies cross-react with sarkosyl-insoluble hyperphosphorylated tau proteins.
Sahara N; Vega IE; Ishizawa T; Lewis J; McGowan E; Hutton M; Dickson D; Yen SH
J Neurochem; 2004 Aug; 90(4):829-38. PubMed ID: 15287888
[TBL] [Abstract][Full Text] [Related]
17. Combined effects of scanning ultrasound and a tau-specific single chain antibody in a tau transgenic mouse model.
Nisbet RM; Van der Jeugd A; Leinenga G; Evans HT; Janowicz PW; Götz J
Brain; 2017 May; 140(5):1220-1230. PubMed ID: 28379300
[TBL] [Abstract][Full Text] [Related]
18. Generation and characterization of new monoclonal antibodies targeting the PHF1 and AT8 epitopes on human tau.
Strang KH; Goodwin MS; Riffe C; Moore BD; Chakrabarty P; Levites Y; Golde TE; Giasson BI
Acta Neuropathol Commun; 2017 Jul; 5(1):58. PubMed ID: 28760159
[TBL] [Abstract][Full Text] [Related]
19. Methods for measuring tau pathology in transgenic mouse models.
Forest SK; Acker CM; d'Abramo C; Davies P
J Alzheimers Dis; 2013; 33(2):463-71. PubMed ID: 22976073
[TBL] [Abstract][Full Text] [Related]
20. Increased neuronal activity in motor cortex reveals prominent calcium dyshomeostasis in tauopathy mice.
Wu Q; Bai Y; Li W; Congdon EE; Liu W; Lin Y; Ji C; Gan WB; Sigurdsson EM
Neurobiol Dis; 2021 Jan; 147():105165. PubMed ID: 33166699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
